We administered questionnaires to medical professionals at our hospital to assess local and systemic adverse reactions after the first, second, and third doses of the COVID-19 vaccine. The results showed that the incidence of local adverse reactions was significantly higher after the third dose than after the second dose; however, there was no significant increase in systemic adverse reactions. Women, individuals with history of allergies, and those aged under 60 years were more likely to report systemic adverse reactions, and the results were consistant with those obtained for the first and second doses. Among those aged over 60 years, the frequency of local and systemic adverse reactions was significantly higher after the third dose than after the second dose, and after the first and second doses, respectively. There were no significant increases in the frequency of skin and mucosal symptoms after the third dose. Patients with skin or mucosal symptoms after the third dose did not necessarily have the same symptoms at the first or second dose.

Alopecia areata (AA) is a disease that greatly affects the patient's appearance and is accompanied by psychosocial and emotional distress. Current treatments mainly focus on the improvement of scalp hair loss; few reports in Japan evaluate the reduction of the psychological burden of AA associated with hair loss improvement. To better understand and evaluate the psychosocial and emotional distress, we summarized the assessments of the burden of AA to explain how it has been evaluated to date. The use of multidirectional evaluations the physician's evaluation of AA symptoms and the patient's evaluation of the disease burden of AA could deepen our understanding of the issues in patients with AA.